PT  - JOURNAL ARTICLE
AU  - Van Vinh Chau, Nguyen
AU  - Nguyet, Lam Anh
AU  - Truong, Nguyen Thanh
AU  - Toan, Le Mau
AU  - Dung, Nguyen Thanh
AU  - Hung, Le Manh
AU  - Nhan, Mai Thanh
AU  - Huy Man, Dinh Nguyen
AU  - Ngoc, Nghiem My
AU  - Thao, Huynh Phuong
AU  - Hoang Tu, Tran Nguyen
AU  - Mai, Huynh Kim
AU  - Hung, Do Thai
AU  - Han Ny, Nguyen Thi
AU  - Thanh, Le Kim
AU  - Anh, Nguyen To
AU  - Thu Hong, Nguyen Thi
AU  - Truc Nhu, Le Nguyen
AU  - Yen, Lam Minh
AU  - Choisy, Marc
AU  - Thanh, Tran Tan
AU  - Thwaites, Guy
AU  - Van Tan, Le
AU  - ,
TI  - Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers
AID  - 10.1101/2021.07.08.21260162
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.08.21260162
4099  - http://medrxiv.org/content/early/2021/07/28/2021.07.08.21260162.short
4100  - http://medrxiv.org/content/early/2021/07/28/2021.07.08.21260162.full
AB  - We studied the immunogenicity of Oxford-AstraZeneca vaccine in Vietnamese healthcare workers. We collected blood samples before each dose, at 14 days after each dose, and month 1 and 3 after dose 1 from each participant alongside demographics data. We measured neutralizing antibodies using a surrogate virus neutralization assay. The 554 study participants (136 males and 418 females) were aged between 22-71 years (median: 36 years). 104 and 94 out of 144 selected participants were successfully followed up at 14 days after dose 2 and 3 months after dose 1, respectively. Neutralizing antibodies increased after each dose, with the sero-conversion rate reaching 98.1% (102/104) at 14 days after dose 2. At month 3 after dose 1, neutralizing antibody levels decreased, while 94.7% (89/94) of the study participants remained seropositive. Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese healthcare workers. The requirement for a third dose warrants further research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust of Great Britain (106680/B/14/Z and 204904/Z/16/Z) and NIH/NIAID (HHSN272201400007C, Subcontract No. S000596-JHU)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of HTD and the Oxford Tropical Research Ethics Committee, University of Oxford, UK.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or its supplementary materials].